PathologyWatch has filed a notice of an exempt offering of securities to raise $25,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, PathologyWatch is raising $25,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Daniel Lambert played a key role in…